|Awarded On||August 21, 2019|
|Title||Emtora Biosciences - using eRapa to treat Familial Adenomatous Polyposis (FAP)|
|Program||Product Development Research|
|Award Mechanism||Seed Awards for Product Development Research|
|Institution/Organization||Rapamycin Holdings Inc.|
|Principal Investigator/Program Director||Frank Taffy|
Emtora Biosciences is a San Antonio, TX company that has developed a novel form of the FDA-approved active ingredient rapamycin, called eRapa. Rapamycin has previously shown promise in treating gastrointestinal diseases and in cancer prevention, but is limited by toxicity. eRapa is targeted to the colon and is delivered at lower doses, resulting in lower toxicity. eRapa is being evaluated to prevent the occurrence of colorectal cancer in patients with Familial Adenomatous Polyposis (FAP). FAP is a rare genetic disease that results in 100’s to 1000’s of benign polyps forming in the colon in the teen years, becoming colorectal cancer by age 39. It is an orphan indication. In mice, eRapa decre...